{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 29 of 122', 'The investigator or designee will assess the eligibility of each subject. All screening', 'procedure results and relevant medical, allergy, and food allergen exposure history must be', 'available before eligibility can be determined. All inclusion criteria must be met and none of', 'the exclusion criteria may apply. No eligibility waivers will be granted.', 'Rescreening may be considered in certain circumstances on a case-by-case basis following', 'approval from the medical monitor.', 'HRQOL questionnaires and bespoke questions are to be completed after determination of', 'eligibility and before randomization as required according to Appendix 4 and Appendix 6,', 'and in the order given in Table 1.', '5.2', 'Treatment Periods', '5.2.1', 'Treatment Period Visit Windows', 'For subjects receiving AR101 treatment, up-dosing visits have a visit window of 3 days', '(ie, 3 days before or after the scheduled visit day) and maintenance visits have a visit window', 'of 7 days. The initial dose-escalation day 1 visit has no visit window. Day 2 should be the', 'next consecutive day after day 1. If circumstances (eg, an intercurrent illness) create a safety', 'risk, day 2 may be delayed up to 7 days after day 1.', 'For subjects receiving standard of care alone, all study visits have a visit window of 7 days,', 'except the day of randomization.', 'Study treatment will continue daily during visit windows. Study product supplies must be', 'considered when scheduling visits.', '5.2.2', 'Randomization Procedures', 'After confirmation of eligibility and completion of HRQOL questionnaires and bespoke', 'questions per Appendix 4 and Appendix 6, study site personnel will access the interactive', 'response system to assign subjects to randomized study treatment (AR101 treatment or', 'standard of care alone), which is to begin within 28 days after signed consent/assent and', 'should be the same day as randomization. Randomized study treatment may start within', '3 days after randomization only if starting the same day is not feasible (eg, for certain', 'unexpected circumstances that may create a safety risk, such as intercurrent illness).', 'A longer window may be allowed on a case-by-case basis following approval from the', 'medical monitor.', '5.2.3 General Study Visit Procedures', 'Day 1 will be the first day of randomized study treatment (AR101 or standard of care alone).', 'All subjects will receive standard of care (Section 5.2.5).', 'Study procedures will be performed at each visit according to the schedules of activities.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 30 of 122', 'Questionnaires are to be completed in the order given in Table 1. Not all questionnaires are', 'completed at the same visits; questionnaires are to be completed at the study visits indicated', 'in Appendix 4, Appendix 5, and Appendix 6.', 'The same parent/caregiver should complete all relevant questionnaires during the study. For', 'age-relevant questionnaires, a subject who transitions from one age group to the next age', 'group during the study will complete the version first used. All subject and parent/caregiver', 'questionnaires will be administered before any clinical or physical assessments or dose of', 'AR101, except as follows:', 'Bespoke questions on assessment of food challenge outcomes will be administered', 'after the food challenge is completed and the results are explained.', 'The European Quality of Life 5-Dimensions health questionnaire (EQ-5D) will also', 'be administered when a severe allergic reaction due to study product or food allergen', 'exposure occurs during an up-dosing visit or at home and 1 week later.', 'Table 1: Order of Subject and Parent/Caregiver Questionnaires To Be Completed', 'Parent/Caregiver', 'Subject Aged 8 to 12 Years', 'Subject Aged 13 to 17 Years', '1', 'EQ-5D-5L', 'EQ-5D-Y', 'EQ-5D-5L', '2', 'FAQL-PB', 'FAQLQ-CF, FAIM-CF', 'FAQLQ-TF, FAIM-TF', '3', 'HADS', 'Bespoke questions on global', 'Bespoke questions on global', 'assessment of HRQOL (child', 'assessment of HRQOL', 'form)', '(teenager form)', '4', 'EQ-5D-Y proxy (for subject', 'Bespoke questions on control of', 'aged 4-7 years)', 'peanut allergy and confidence in', 'managing allergic reactions', '(teenager form)', '5', 'FAQLQ-PF, FAIM-PF (for', 'Bespoke questions on', 'subject aged 12 years);', 'assessment of food challenge', 'FAQLQ-PFT, FAIM-PFT (for', 'outcomes (patient form) [1]', 'subject aged 13-17 years)', '6', 'Bespoke questions on global', 'TSQM-9 (for AR101-treated', 'assessment of HRQOL', 'subject at early', '(parent/caregiver form)', 'discontinuation/study exit)', '7', 'Bespoke questions on control of', 'Bespoke exit questionnaire', 'peanut allergy and confidence in', '(patient form, for AR101-treated', 'managing allergic reactions', 'subject at early', '(parent/caregiver form)', 'discontinuation/study exit)', '8', 'Bespoke questions on', 'Qualitative exit interview (for', 'assessment of food challenge', 'AR101-treated subject at early', 'outcomes (parent/caregiver', 'discontinuation/study exit) [2]', 'form) [1]', '9', 'TSQM-9 (for AR101-treated', 'subject aged 4-12 years at early', 'discontinuation/study exit)', '10', 'Bespoke exit questionnaire', '(parent/caregiver form, for']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 31 of 122', 'Parent/Caregiver', 'Subject Aged 8 to 12 Years', 'Subject Aged 13 to 17 Years', 'AR101-treated subject at early', 'discontinuation/study exit)', '11', 'Qualitative exit interview (for', 'AR101-treated subject at early', 'discontinuation/study exit) [2]', 'Questionnaires are to be completed at the study visits indicated in Appendix 4, Appendix 5, and Appendix 6.', '[1] To be completed after the end of the observation period for the food challenge (OLFC or optional', 'RWPC) and after the results are explained.', '[2]', 'To be conducted in a random sample of parents/caregivers and subjects aged > 13 years at study exit or', 'early discontinuation.', 'EQ-5D-5L, European Quality of Life 5-Dimensions 5-Levels health questionnaire; EQ-5D-Y, EQ-5D Youth;', 'FAIM, Food Allergy Independent Measure; FAIM-CF, FAIM - child form; FAIM-PF, FAIM - parent form;', 'FAIM-PFT, FAIM - parent form teenager; FAIM-TF, FAIM - teenager form; FAQL-PB, Food Allergy', 'Quality of Life - Parental Burden; FAQLQ, Food Allergy Quality of Life Questionnaire; FAQLQ-CF,', 'FAQLQ - child form; FAQLQ-PF, FAQLQ - parent form; FAQLQ-PFT, FAQLQ - parent form teenager;', 'FAQLQ-TF, FAQLQ - teenager form; HADS, Hospital Anxiety and Depression Scale;', 'HRQOL, health-related quality of life; OLFC, open-label food challenge; RWPC, real-world peanut', 'challenge; TSQM-9, Treatment Satisfaction Questionnaire for Medication.', '5.2.4', 'General Procedures for Subjects Receiving AR101 Treatment', 'Before administration of the first and any subsequent dose of AR101 at the study site, the', \"subject's health status must be at baseline state, including no presence of active wheezing,\", 'flare of atopic disease (eg, atopic dermatitis), or suspected intercurrent illness. The subject', 'must have fully recovered from any previous illness for at least 3 days, depending on the', 'severity of the illness per investigator assessment.', 'A study physician must always be readily available during dosing at the study site. At', 'minimum, subjects will be evaluated for signs and symptoms of an allergic reaction at 15 to', '30 minutes postdose and every 30 minutes thereafter (with vital signs measurements of blood', 'pressure and heart rate), until at least 90 minutes postdose or the end of the observation', 'period, whichever is last. The postdose observation period may be shortened to 30 minutes', 'during maintenance if no allergy symptoms occurred during the previous 3 maintenance', 'visits.', 'Allergy symptoms will be assessed as follows:', 'Symptoms of allergic reactions will be evaluated per Section 8.5.1.', 'The tolerability of study product will be evaluated per Section 8.5.1.2.', 'The treatment of allergic reactions and dose adjustment of study product will follow', 'guidelines per Sections 8.5.2 and 8.5.3.']", "completion": ""}